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Abstract 
A distinctive feature of Plasmodium vivax infections is the overall low parasite density in peripheral blood. Thus, iden-
tifying asymptomatic infected individuals in endemic communities requires diagnostic tests with high sensitivity. The 
detection limits of molecular diagnostic tests are primarily defined by the volume of blood analysed and by the copy 
number of the amplified molecular marker serving as the template for amplification. By using mitochondrial DNA as 
the multi-copy template, the detection limit can be improved more than tenfold, compared to standard 18S rRNA 
targets, thereby allowing detection of lower parasite densities. In a very low transmission area in Brazil, application of 
a mitochondrial DNA-based assay increased prevalence from 4.9 to 6.5%. The usefulness of molecular tests in malaria 
epidemiological studies is widely recognized, especially when precise prevalence rates are desired. Of concern, how-
ever, is the challenge of demonstrating test accuracy and quality control for samples with very low parasite densities. 
In this case, chance effects in template distribution around the detection limit constrain reproducibility. Rigorous 
assessment of false positive and false negative test results is, therefore, required to prevent over- or under-estimation 
of parasite prevalence in epidemiological studies or when monitoring interventions.
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Background
Parasite densities in Plasmodium vivax infections are 
generally lower compared to Plasmodium falciparum 
densities. For example, in Papua New Guinea (PNG), 
among children living in an area with similar P. falcipa-
rum and P. vivax transmission rates, the difference in 
mean parasite density between both species was ten-fold 
by light microscopy (LM) and 30-fold by quantitative 
PCR (qPCR) (Fig. 1) [1]. A similar difference in densities 
between both species was observed in the general popu-
lation [2]. The lower parasite densities of P. vivax can be 
explained by the strict host cell preference of this species, 
which infects only reticulocytes that account for less than 
1% of all erythrocytes. P. falciparum is less restricted 
in host cell selection and, thus, can reach higher densi-
ties. Moreover, age trends in infection prevalence and 
clinical incidence suggest an earlier acquisition of clini-
cal immunity and more effective control of parasitaemia 
for P. vivax compared to P. falciparum [3]. In a cohort of 
young children from PNG (1–4  years), the incidence of 
clinical P. vivax episodes decreased significantly by the 
second year of life, whereas the incidence of clinical P. 
falciparum episodes continued to rise up to 4 years of age 
[3]. This indicates that young children in endemic areas 
acquire the ability to effectively control P. vivax parasitae-
mia early in life.
The overall lower density of P. vivax compared to P. fal-
ciparum plays a critical role in limiting the test sensitivity 
of diagnostic methods used to measure parasite preva-
lence, such as light microscopy (LM), rapid diagnostic 
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test (RDT) and quantitative PCR (qPCR). A systematic 
review of sub-microscopic P. vivax infections showed 
that in cross-sectional surveys from diverse transmission 
settings, an average 67% of all P. vivax infections were 
sub-microscopic and would thus remain undetected by 
LM [4]. As for P. falciparum, a negative relationship was 
observed between the proportion of sub-microscopic 
infections and prevalence by LM. In view of the lower P. 
vivax densities overall, molecular-based diagnostic tools 
are even more relevant for detection of P. vivax than for 
P. falciparum, particularly in areas of low transmission. 
In this paper, diagnostics for detecting P. vivax blood 
stage infections are discussed. Hypnozoites, another hall-
mark of P. vivax infections, cannot be detected by current 
diagnostic methods.
Diagnostic tools for surveillance
LM has traditionally been the gold standard for malaria 
epidemiology, while prevalence by LM has been used 
to describe malaria transmission levels globally. Having 
made substantial progress in malaria control, interven-
tions have shifted focus from targeting clinical cases only 
towards identifying and treating asymptomatic parasite 
carriers, as well. Hence, the extent of sub-microscopic 
Plasmodium infections and the ability of molecular diag-
nostic tools to detect them have increasingly attracted 
attention [4, 5]. The limited sensitivity of LM compared 
to molecular diagnosis derives from the very small vol-
ume of blood (0.025–0.0625  µL whole blood) examined 
per blood slide for parasite counts in field studies [6]. 
Molecular techniques permit examination of an equiva-
lent of 5–10  µL whole blood, which increases test sen-
sitivity substantially. However, using increasingly high 
blood volumes in molecular diagnostic tests would not 
necessarily result in a linear increase in sensitivity, as 
large amounts of human genomic DNA will act as PCR 
inhibitor. Attempts to maximize molecular test sensi-
tivity by increasing the input material to several mL of 
venous blood would require depletion of human white 
blood cells [7].
To increase the comparability of molecular-epidemi-
ological data generated across different field sites and 
laboratories, a defined set of experimental details should 
be included in any report. These recommended specifica-
tions are presented in Box 1.
For diagnosing community samples, the desired pro-
file of a diagnostic test differs from that of clinical man-
agement. For example, control interventions targeting 
all individuals who may contribute to malaria transmis-
sion require robust diagnosis of low density infections in 
asymptomatic parasite carriers. In response to this need, 
experts in P. vivax diagnostics and epidemiology recently 
defined target product profiles (TPP) for P. vivax diag-
nosis in malaria epidemiological field work [8]. Three 
P. falciparum (qPCR) 
Median (IQR): 335 (42-2142) copies/µl blood
Geometric mean: 364 copies/µl blood
P. vivax (qPCR) 
Median (IQR): 12 (4-26) copies/µl blood
Geometric mean: 9 copies/µl blood
P. falciparum (LM) 
Median (IQR): 805 (272-9680) parasites/µl blood
Geometric mean:       1412 parasites/µl blood
P. vivax (LM) 
Median (IQR): 89 (57-213) parasites/µl blood
Geometric mean: 119 parasites/µl blood
a b
Fig. 1 Parasite densities of P. falciparum and P. vivax measured by qPCR (a) and light microscopy (b) in community samples from PNG (5–9 years old 
children from 6 neighbouring villages) (Data taken from [41])
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distinct TPPs for the next generation of P. vivax diagnos-
tic tests for control and elimination were generated under 
the leadership of the Foundation for Innovative Diagnos-
tics (FIND). Each TPP addressed a particular diagnostic 
task: (i) a point-of-care tool for clinical case management 
(e.g. an ultra-sensitive RDT for P. vivax); (ii) a molecular 
ultra-sensitive test for mobile teams engaged in surveil-
lance-response activities targeting asymptomatic carriers 
that can be performed rapidly, in a single tube and at the 
point-of-care; and (iii) a molecular ultra-sensitive test for 
large-scale surveillance activities or research where the 
time to result is not critical, and that can be performed at 
high throughput and low cost at a core facility [8]. Molec-
ular assays that target multiple copies per genome have 
the potential to increase test sensitivity sufficiently to 
allow pooling of several samples without compromising 
test sensitivity. Using pooling for the last two tasks can 
reduce costs, particularly in areas of low P. vivax preva-
lence (< 2%).
Plasmodium vivax 18S rRNA as marker gene 
for DNA‑ and RNA‑based detection
18S rRNA genes are the standard molecular markers for 
differentiating Plasmodium species. In the two P. vivax 
reference genomes sequenced, Sal1 and P01, three dis-
tinct 18S rRNA copies exist and are expressed in differ-
ent developmental stages (Additional file 1: Table S1) [9]. 
However, a widely used Pv18S RNA assay [10] targets 
only one of the three Pv18S rRNA copies by qPCR.
In contrast to P. falciparum, schizont stages of P. vivax 
are found in the peripheral blood [11]. As schizonts can 
contain 16–24 genomes, a direct conversion from copy 
number to parasite counts will not be accurate. This issue 
has been investigated using digital droplet PCR (ddPCR), 
a technology that permits absolute quantification of tem-
plate DNA [12]. A very strong correlation (R = 0.86) was 
found for P. vivax quantification by the two molecular 
methods, ddPCR and standard Pv18S rRNA qPCR [12]. 
The correlation between P. vivax microscopy counts and 
quantification by ddPCR and qPCR was good (R = 0.72 
and R = 0.73, P < 0.0001) [12]. Similar correlations were 
observed for P. falciparum, thus, it seems that the occa-
sional presence of P. vivax late stages in finger-prick 
blood samples does not substantially affect molecular 
quantification. The number of Pv18S rRNA gene copies 
detected per parasite was determined by comparing with 
LM data. On average, one Pv18S rRNA copy per parasite 
was measured by ddPCR. As multiple genomes should be 
detected per schizont, a loss or damage of genomic cop-
ies during DNA extraction has to be assumed [12].
The same Pv18S rRNA assay can also be used to target 
Pv18S rRNA transcripts instead of the genes themselves 
[10, 13, 14]. Targeting RNA transcripts amplifies sen-
sitivity, since each ribosome carries one copy of rRNA, 
which amounts to thousands of 18S rRNA transcripts per 
cell. For P. falciparum, a factor to convert Pf18S rRNA 
transcripts into parasite counts was established using 
synchronous cultured parasites [13].  104 18S rRNA tran-
scripts were measured per ring stage parasite; this num-
ber remained constant for the initial 24-h of the life cycle. 
As P. vivax cannot be readily cultured in vitro, a conver-
sion factor for P. vivax only could be estimated using 
Box 1 Recommended reporting of experimental details in molecular‑epidemiological studies
Technical details should be reported according to MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments [50]
Requirement for publication Experimental information to be reported
Imperative Sampling details of finger prick or venous blood sampling; e.g. type of filter paper (treated or not), microtainer/tubes 
(heparin, EDTA), storage solution (RNAprotect/Trizol)
Description of extraction method; e.g. extracted blood volume, spin columns, chelex, type of DNAse treatment of puri-
fied RNA
Resuspension/elution volume for extracted DNA or RNA
Description of molecular target; e.g. Gene ID, amplicon size, primer and probe sequences
Reagent concentrations and total reaction volume; e.g. concentrations of primer/probe, template volume added to 
amplification reaction
Standard used for quantification; e.g. parasite trendline (with stage composition), NIBSC WHO reference standard, 
plasmid (linearized/supercoiled)
Clear definition of quantification results; e.g. method used for conversion of copy numbers into parasites/µL blood, clear 
denominator for “template copy number/µL whole blood or DNA”
Assay performance parameters; e.g. specificity, assay LOD, PCR efficiency
Optional Storage conditions and time prior to extraction, e.g. of filter papers or whole blood, temperature, desiccant, particularly 
for filter papers
Reproducibility; e.g. results from duplicates or triplicates
Comparison to LM; e.g. correlation of parasite counts/µL blood
to copy numbers/µL blood
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parasite counts by LM from field samples [10]. Correla-
tion between microscopic P. vivax counts and the num-
ber of Pv18S rRNA transcripts was moderate  (r2 = 0.44) 
[10]. The discrepancies between LM and molecular quan-
tification might derive from between-sample variation 
in parasite stage composition or from RNA content per 
parasite. Additionally, variable conditions of RNA preser-
vation and sample storage in the field affect the quality 
of extracted RNA, making RNA-based quantification less 
reliable compared to DNA-based quantification.
Problems caused by targeting transcripts 
of Plasmodium vivax 18S rRNA
During nucleic acid extraction, there is an inherent risk of 
contaminating parasite negative samples handled along-
side parasite positive samples. Cross-contamination can 
occur even without pipetting errors, by spreading aero-
sols when handling highly concentrated nucleic acids. 
Thus, the greatest care needs to be taken when working 
with clinical samples for both DNA and RNA template 
molecules. In view of the exceedingly high copy numbers 
of ribosomal RNA transcripts compared to genomic 18S 
rRNA copies, this contamination threat is potentiated by 
working at RNA level, leading to false positivity [10, 15].
This risk of cross-contamination was addressed in a 
cross-sectional survey of 315 children from PNG, where 
DNA-based and RNA-based detection and quantifica-
tion were compared for P. vivax and P. falciparum [10]. 
Figure 2 shows the number of P. falciparum and P. vivax 
18S rRNA transcripts in study participants, plotted by 
decreasing number of 18S rRNA transcripts. For P. fal-
ciparum, transcript numbers trailed off over a substan-
tial number of samples at the lower density end (<  10 
transcripts, 40% of all positive samples). This was not 
observed for P. vivax, which may be explained by the 
lower median parasite density (8 times lower by LM and 
by qPCR) in P. vivax positive samples compared to P. fal-
ciparum infections of the same study.
The potential for cross-contamination between the wells 
of an RNA extraction plate was investigated by analysing 
large numbers of negative controls (phosphate-buffered 
saline, PBS) in parallel with interspersed wells contain-
ing high density P. falciparum 3D7 culture, mimicking 
high density clinical infections. False positive results were 
observed in some of the wells neighbouring high-density 
samples. These confirmed false positives were typically 
characterized by transcript numbers < 10 transcript cop-
ies/µL and in very few exceptions  <  50 copies/µL. Such 
high parasitaemia, as used in these control experiments, 
might be reached only rarely in community samples, yet, 
this observation calls for great care during extraction 
and pipetting. Analysis of the PNG field samples (Fig. 2) 
led to the conclusion that for P. falciparum, a cut-off for 
positivity was required when detecting Pf18S rRNA tran-
scripts, to exclude false positive results caused by low-key 
contamination from the few intermittent high density 
infections. Based on the distribution of Pv18S rRNA tran-
script copy numbers (Fig. 2b), a cut-off for P. vivax RNA-
based parasite detection and quantification did not seem 
necessary. In summary, the pitfalls of RNA-based diag-
nosis do not reject parasite detection based on 18S rRNA 
transcripts, but rather call for awareness, utmost caution 
and well-controlled experimental procedures.
Plasmodium vivax assays targeting multi‑copy 
templates
High-copy genomic sequences can serve as new PCR 
targets for the detection of malaria infections, providing 
increased sensitivity over single- or low-copy 18S rRNA 
genes, without the pitfalls of RNA-based amplification. 
Furthermore, multi-copy markers have the potential to 
allow sample pooling without jeopardizing test sensitiv-
ity. This would be particularly favourable in the context 
of increasingly large study sizes required for community 















































Fig. 2 Detection of 18S rRNA genomic copies compared to 18S rRNA 
transcripts. Data used for this blot derived from earlier published work 
[10]. Dashed line: choice of cut-off (> 10 transcripts per reaction)
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The P. vivax genome was mined to identify species-
specific, repetitive sequences. The best target identified 
was the non-coding subtelomeric repeat sequence Pvr47, 
which occurs in 14 copies per P. vivax Sal1 genome [16]. 
A Pvr47-based single-step PCR assay was almost as sen-
sitive as nested PCR targeting the P. vivax 18S rRNA 
when visualized in an agarose gel [16]. Attempts to use 
Pvr47 for designing a LAMP assay failed due to speci-
ficity problems [17]. When the Pvr47 assay was used to 
detect P. vivax in Anopheles spp. mosquitoes, non-spe-
cific bands and sequences were produced [18].
A number of attempts were made to identify other 
multi-copy markers for detection of P. vivax. Similar to 
a qPCR assay developed for ultra-sensitive detection 
of P. falciparum that targets the conserved C-terminus 
of the var gene family [19], P. vivax candidates were 
sought among the vir/pir multigene family [20, 21]. How-
ever, genetic diversity among members of this family is 
extremely large, such that no DNA stretches of sufficient 
sequence conservation and size for primer and probe 
design were identified [22]. Recently, a revised P. vivax 
reference genome (P01) with improved assembly of the 
subtelomeres became available [23]; new attempts are 
currently underway to identify multi-copy targets.
In view of the high genetic variability in repeated 
genomic regions and in the vir genes of P. vivax, mitochon-
drial DNA (mtDNA) offers relatively conserved regions 
for primer design, as well as sufficient diversity for distin-
guishing the different Plasmodium species. The mitochon-
drial genome of malaria parasites is present in multiple 
copies per cell, contained in a single mitochondrion. For 
P. falciparum, the total number per ring stage parasite is 
about 20 mitochondrial genomes [24]. The bulk of these 
copies are present in linear tandem arrays of 3–4 units 
[25]. Replication occurs simultaneously with the nuclear 
genome, about 24-h post invasion. For P. falciparum with 
sequestered late stages, the gain in sensitivity from using 
a mitochondrial marker compared to nuclear markers is 
potentially limited, as the multiple copies of mitochondrial 
DNA (mtDNA) are not distributed independently, but in 
six molecules, each composed of the 3–4 tandem repeat 
units of mtDNA. In P. vivax, however, late stages with mul-
tiple genomes and the replicating mitochondrial genomes 
are also present in peripheral blood. While the organiza-
tion of P. vivax mtDNA is not known, a substantial tem-
plate multiplication factor can be expected. Thus, the gain 
in sensitivity from targeting the mitochondrial genome 
might be greater for P. vivax than for P. falciparum.
A number of assays for diagnosing P. vivax have tar-
geted mtDNA: one-step PCR; loop-mediated isother-
mal amplification (LAMP) or qPCR, targeting the 
cytochrome C oxidase I gene (cox1) [26–29]; genus-
specific PCR, targeting non-coding regions between the 
cytochrome B gene (cytB) and cox1 [30]; nested PCR, tar-
geting cytochrome C oxidase III (cox3) [31]; and genus-
specific nested PCR, targeting the cyt B gene, followed by 
sequencing of the PCR product or restriction fragment 
length polymorphism (PCR–RFLP) for species identifica-
tion [32, 33].
Targeting mitochondrial DNA by qPCR 
in cross‑sectional samples from Brazil
A qPCR assay was designed to target the P. vivax mito-
chondrial cox1 gene (Pv-mtCOX1 qPCR, Additional 
file  2: Table S2). This assay showed performance char-
acteristics superior to Pv 18S rRNA qPCR (Additional 
file  3: Table S3, Additional file  4: Table S4). Some 604 
samples collected from a cross-sectional survey in the 
Amazonas region, Brazil, in 2014 were re-analysed with 
Pv-mtCOX1 qPCR to investigate the effect of applying 
highly sensitive DNA-based parasite detection to com-
munity samples and asymptomatic parasite carriers. The 
number of P. vivax positive samples differed substan-
tially by assay and 23.8% of positive samples were only 
detected by the Pv-mtCOX1 assay (Fig. 3a). Overall posi-
tivity was very low, with 4.9%  (CI95 [3.4–6.9%]) of sam-
ples testing positive by 18S rRNA qPCR and 6.5%  (CI95 
[4.7–8.7%]) by Pv-mtCOX1 qPCR. In samples deemed 
positive by both assays, the correlation of template copy 
numbers obtained by the two assays was good (Spear-
man’s rho = 0.85, red data points in Fig. 3b).
To investigate the relationship between template copy 
number and positivity, copy numbers were plotted for 
all positive samples for both assays (Fig.  4; Additional 
file  5: Figure S1). The median gene copy number for 
Pv-mtCOX1 was about ten times higher than for Pv18S 
rRNA. Infections of very low parasitaemia were detected 
by Pv-mtCOX1 qPCR but not by Pv18S rRNA qPCR. 
These results confirm the mitochondrial genome as a 
suitable target for achieving a substantially more sensi-
tive qPCR assay, enabling detection of scarce mitochon-
drial template copies in very low density infections.
Loop‑mediated isothermal amplification (LAMP)
LAMP assays amplify single-copy or multi-copy molecu-
lar markers in an isothermal reaction. This method seems 
optimally suited for application at the point-of-care 
(POC) in field settings. LAMP requires little in the way 
of equipment and may be carried out by mobile labora-
tories. LAMP is suitable for detecting sub-microscopic 
infections [34, 35]. However, LAMP cannot quantify 
parasitaemia and some protocols for measuring ampli-
fication are not very robust, such as hydroxynaphtol 
blue detection (Additional file  6: Figure S2). The use of 
fluorescent dyes to detect LAMP products can overcome 
some of the limitations of conventional LAMP detection.
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Unspecific template-independent amplification is a 
long-standing problem in LAMP that has been addressed 
by a number of authors [36–38]. Amplification artefacts 
arise from primer complexes formed by the four to six 
primers per reaction, two of which are very long prim-
ers pre-designed for generating loops. Primer dimers or 
junk amplification products may be generated in nega-
tive controls. False-positive LAMP reactions reportedly 
occurred at random [34]. This phenomenon leads to 
loss of confidence in results, as this type of amplification 
artefact cannot be distinguished from reagent contami-
nation. Moreover, it is difficult to validate true positivity 
at ultralow template concentrations around the limit of 
detection. Systematic validation is further complicated by 
chance effects in template distribution in low densities.
To improve the specificity of LAMP, several assay 
parameters were optimized, such as decreasing the 
primer concentration, reducing the incubation time of 
the LAMP reaction, testing different published primer 
sets, and optimizing primers (unpublished own results) 
using commercial (Mast Isoplex Malaria Lamp Kit; Mast 
Diagnostica) as well as home-made master mixes made 
up of individually purchased reagents (New England Bio-
labs). False positive results were primarily obtained with 
primers targeting the 18S rRNA genes of the genus Plas-
modium [39]. Using alternative primers that target the 
mitochondrial genome of the genus Plasmodium [35], 
false-positive results in negative controls were substan-
tially reduced but not eliminated. Amplification of LAMP 
products can be tracked in real-time using a StepOne 
thermocycler to detect the fluorescent dye of a commer-
cial master mix. In negative controls, signals from unspe-
cific amplification appeared later in the reaction than 
signals from the true positive reaction observed when 
a template was present. However, positive samples with 
low parasite densities equivalent to 1 parasite/µL could 
not be distinguished from false-positives (Additional 
file  7: Figure S3). Duration of incubation was a crucial 
determinant for false-positive results. Some published 
protocols incubate LAMP for 60  min, for example [39], 
whereas LAMP kit manuals allot 40 min. To avoid false-
positive results, reaction time should not be extended, 
even though this might result in a potential loss of sen-
sitivity by missing low density infections. When a com-
mercial LAMP Kit with lyophilized primers (EIKEN 
Fig. 3 Comparison of Pv-mtCOX1 and Pv18S rRNA assays performed in parallel in 604 community samples from Brazil. a Overlap in positivity by 
Pv-mtCOX1 and Pv18S rRNA qPCR. b Correlation of log10 template copy numbers detected by Pv-mtCOX1 and Pv18S rRNA qPCR
Fig. 4 Copy numbers of each marker gene detected per sample. 
Each dot represents one sample, red indicates all samples positive 
for Pv18S rRNA qPCR, orange indicates samples detected only by Pv-
mtCOX1 qPCR. Dashed line: Molecular assays have a theoretical LOD, 
i.e., at least 1 template copy must be present per PCR reaction
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CHEMICAL CO., LTD) was used, unspecific amplifica-
tion was only rarely observed.
Consequences of false‑positive and false‑negative 
test results
To guide malaria control and surveillance, reliable preva-
lence data is of great importance, particularly in areas 
with low endemicity or in regions recently declared 
malaria-free. False-positive test results lead to overesti-
mation of residual malaria transmission and may cause 
unnecessary concerns. In contrast, a large extent of false-
negative results would underestimate the true transmis-
sion intensity. However, such underestimation is usually 
expected, as epidemiologists and public health workers 
are well aware of imperfect malaria diagnosis.
What should be the guiding principle for selecting the 
most suitable diagnostic test? The dilemma consists in a 
trade-off between sensitivity and false-positivity, as seen 
in selecting the incubation time for a LAMP reaction, or 
in the use of RNA-based parasite detection by qRT-PCR. 
Evidently, the conservative and more stringent results are 
preferable because the detectability of parasites in ultra-
low infections is always imperfect. The most appropriate 
nucleic acid amplification technique (NAAT) must be 
chosen in consideration of the task in question. For exam-
ple, for focal screen and treat or surveillance-response 
activities, high sensitivity might be more important than 
an occasional false-positive result. Thus, any decision 
about which diagnostic methods to use should be aligned 
with each specific task and consider the limitations of the 
diagnostics applied.
It is important to keep in mind that stochastic variation 
in results is always observed when infections are around 
the limit of detection of a given assay. For example, when 
150 samples collected in PNG were screened three times 
with the same P. vivax 18S rRNA assay, only 14 infections 
were detected in all three replicates, while 19 infections 
were detected in only one or two replicates. This varia-
tion was less pronounced for P. falciparum (24/31 infec-
tions detected in all three replicates), most likely due to 
the overall higher density of P. falciparum [12]. Thus, 
when results are compared between field laboratories 
and reference laboratories, slightly different results are 
expected, even when using the same protocols. Only if a 
laboratory repeatedly detects fewer infections compared 
to a reference laboratory do lab-specific procedures have 
to be optimized.
Relevance of detecting ultralow parasite densities
The limited resources in malaria endemic areas war-
rant a discussion on whether molecular diagnostics and 
the establishment of qPCR assays in field laboratories 
are needed. For P. vivax, NAAT seem more necessary 
than for P. falciparum. The P. vivax-specific diagnostic 
challenges include lower mean parasite densities, less 
sensitive RDTs and a greater need for diagnosis of all 
infections to prevent later relapses and, thus, continued 
transmission [8]. These challenges can be tackled to some 
extent by molecular diagnostics, but all diagnostic meth-
ods, including NAAT, sooner or later reach a test-specific 
limit of detection. Test sensitivity largely depends on the 
volume of blood used for DNA or RNA extraction and 
on the whole blood equivalent added to the amplification 
reaction. Increasing test sensitivity beyond the current 
levels of detection would require venous blood samples 
and white blood cell depletion [40]. That option is not 
considered feasible for large-scale field surveys. Thus, 
detection of malaria parasites remains imperfect.
However, if capacity, equipment and reagents were 
available in P. vivax endemic areas, those facilities could 
act as reference laboratories for quality assurance. This 
would greatly help to improve diagnostic quality in 
research and surveillance. The answer to the question 
about molecular diagnostics being essential or not largely 
depends on the specific task, be it rapid reactive response 
or general surveillance, research or clinical trial.
The usage of molecular diagnosis for understanding the 
reservoir of transmission and to guide interventions has 
been emphasized by many recent publications [41–45], 
but the epidemiological relevance of detecting submicro-
scopic P. vivax infections is not the primary focus of this 
publication.
Gametocytes in low density P. vivax infections
Treatment of asymptomatic P. vivax infections has two 
aims: firstly, to target gametocytes to prevent onward 
transmission to mosquitoes and, secondly, to target 
dormant liver stages to prevent relapses. Blood-stage 
infections originating from relapses frequently carry 
gametocytes and, thus, likely also contribute to transmis-
sion [46].
In the context of transmission control, the question 
arises whether all low intensity P. vivax infections carry 
gametocytes and whether molecular tools are required to 
determine the prevalence of gametocytes in the popula-
tion. Plasmodium vivax gametocytes are detected either 
by LM or by quantifying transcripts of genes that are 
specifically expressed in P. vivax gametocytes. P. vivax 
gametocytes are difficult to distinguish from trophozo-
ites by LM. Molecular detection of gametocytes is more 
sensitive and more precise. The standard marker gene 
pvs25 encodes an ookinete surface protein. Quantitative 
reverse transcription PCR (qRT-PCR) is performed on 
RNA extracted from a blood sample [10]. Gametocyte 
detection in field surveys is complicated by the require-
ment for appropriate RNA-stabilizing procedures, such 
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as immediate transfer of a blood sample into a stabiliz-
ing reagent [10]. When pvs25 transcript numbers were 
plotted against Pv18S rRNA gene copies, a moderate 
correlation (R = 0.59) was observed in samples from two 
cross-sectional community surveys conducted in PNG 
(Fig. 5) [2, 41]. A much stronger correlation  (r2 =  0.82) 
was observed in a study from Thailand, using the same 
diagnostic methods [44]. P. vivax gametocytes can be 
detected within 3 days of the appearance of asexual para-
sites in the blood [47]. This also argues for using P. vivax 
blood stage parasites as a surrogate marker for gameto-
cytaemia. Performing gametocyte detection and quantifi-
cation assays are not required for surveillance.
Asymptomatic infections were often found to carry 
gametocytes in studies in Brazil, Thailand and PNG [2, 
44, 48]. The global trend of declining P. vivax malaria 
entails reduced mean population parasite densities and, 
thus, a lower proportion of infections carrying detectable 
gametocytes [2]. How much these low density infections 
contribute to transmission remains unclear. An indica-
tion that low density infections may be relevant derives 
from mosquito feeding assays conducted in Thailand, 
showing that P. vivax infections < 10 parasites/µL can be 
infective, though only rarely and yielding few oocyts [49]. 
Similarly, mosquito feeding assays will be required to 
determine the infectivity of P. vivax gametocytes follow-
ing drug treatment. Transmission during convalescence 
might be relevant in elimination settings, where levels of 
acquired immunity are low and therefore a large propor-
tion of all those infected will seek treatment.
Conclusions
Key points with particular relevance for P. vivax diagno-
sis in community samples:
  • The input blood volume determines test sensitivity. 
To improve test performance, the volume of finger 
prick blood processed or DNA and RNA template 
added to NAAT should always be maximized.
  • Multi-copy targets used for qPCR are superior for 
detection and necessary for pooling samples before 
molecular analysis. The tenfold increase of PCR tem-
plates per cell when using the Pv-mtCOX1 assay led 
to gains in positivity and more precise prevalence 
estimates in a cross-sectional survey in Brazil.
  • The suitability of RNA-based assays is questionable 
for processing large-scale field samples with a wide 
range of parasite densities. A fully enclosed system 
for sample processing and tight controls seem critical 
to avoid false-positivity.
  • Different numbers of genomes per P. vivax blood 
stage do not permit simple quantification of parasi-
taemia or gametocytaemia. The most robust quantifi-
cation consists of the copy numbers of the molecular 
marker detected per µL of whole blood equivalent.
  • There is no need for specific gametocyte assays in 
surveillance and monitoring of interventions, as P. 
vivax asexual densities and gametocyte densities are 
well correlated.
  • Some limitations for NAAT cannot be resolved, such 
as imperfect detection derived from restrictions in 
blood volume, sampling procedures in the field or 
chance effects in detecting a very low abundant PCR 
template.
  • It is important to investigate methodological limita-
tions and shortfalls of the diagnostic techniques used 
and consider their effects on clinical trial outcomes, 
as well as on the planning of interventions.
  •
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